404 related articles for article (PubMed ID: 17700155)
21. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153
[TBL] [Abstract][Full Text] [Related]
22. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting.
Taussig DC; Davies AJ; Cavenagh JD; Oakervee H; Syndercombe-Court D; Kelsey S; Amess JA; Rohatiner AZ; Lister TA; Barnett MJ
J Clin Oncol; 2003 Aug; 21(16):3060-5. PubMed ID: 12915594
[TBL] [Abstract][Full Text] [Related]
23. Graft failure following reduced-intensity cord blood transplantation for adult patients.
Narimatsu H; Kami M; Miyakoshi S; Murashige N; Yuji K; Hamaki T; Masuoka K; Kusumi E; Kishi Y; Matsumura T; Wake A; Morinaga S; Kanda Y; Taniguchi S
Br J Haematol; 2006 Jan; 132(1):36-41. PubMed ID: 16371018
[TBL] [Abstract][Full Text] [Related]
24. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age.
Konuma T; Takahashi S; Ooi J; Tomonari A; Tsukada N; Kato S; Sato A; Monma F; Kasahara S; Nagamura-Inoue T; Uchimaru K; Iseki T; Tojo A; Yamaguchi T; Asano S
Ann Hematol; 2009 Jun; 88(6):581-8. PubMed ID: 19030858
[TBL] [Abstract][Full Text] [Related]
25. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
27. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT).
Cornetta K; Laughlin M; Carter S; Wall D; Weinthal J; Delaney C; Wagner J; Sweetman R; McCarthy P; Chao N
Biol Blood Marrow Transplant; 2005 Feb; 11(2):149-60. PubMed ID: 15682076
[TBL] [Abstract][Full Text] [Related]
28. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.
Magro E; Regidor C; Cabrera R; Sanjuán I; Forès R; Garcia-Marco JA; Ruiz E; Gil S; Bautista G; Millán I; Madrigal A; Fernandez MN
Haematologica; 2006 May; 91(5):640-8. PubMed ID: 16670070
[TBL] [Abstract][Full Text] [Related]
29. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation.
Przepiorka D; Petropoulos D; Mullen CA; Danielson M; Mattewada V; Chan KW
Bone Marrow Transplant; 1999 Jun; 23(12):1291-5. PubMed ID: 10414918
[TBL] [Abstract][Full Text] [Related]
30. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
31. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.
Bradley MB; Satwani P; Baldinger L; Morris E; van de Ven C; Del Toro G; Garvin J; George D; Bhatia M; Roman E; Baxter-Lowe LA; Schwartz J; Qualter E; Hawks R; Wolownik K; Foley S; Militano O; Leclere J; Cheung YK; Cairo MS
Bone Marrow Transplant; 2007 Oct; 40(7):621-31. PubMed ID: 17660841
[TBL] [Abstract][Full Text] [Related]
32. Cord blood transplantation for adult patients with hematological malignancies.
Yamane T; Nakamae H; Hasegawa T; Terada Y; Hagihara K; Ohta K; Hino M
Osaka City Med J; 2005 Dec; 51(2):83-8. PubMed ID: 16617685
[TBL] [Abstract][Full Text] [Related]
33. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.
Wang X; Liu H; Li L; Geng L; Ding K; Liu X; Tong J; Zhu W; Sun Z
Eur J Haematol; 2012 Jan; 88(1):39-45. PubMed ID: 21933279
[TBL] [Abstract][Full Text] [Related]
34. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
[TBL] [Abstract][Full Text] [Related]
35. Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Kusumi E; Kami M; Kanda Y; Murashige N; Seki K; Fujiwara M; Koyama R; Komatsu T; Hori A; Tanaka Y; Yuji K; Matsumura T; Masuoka K; Wake A; Miyakoshi S; Taniguchi S
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1302-9. PubMed ID: 17162212
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
[TBL] [Abstract][Full Text] [Related]
37. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
[TBL] [Abstract][Full Text] [Related]
38. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
[TBL] [Abstract][Full Text] [Related]
40. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
